image
Healthcare - Medical - Devices - NASDAQ - US
$ 1.26
-2.33 %
$ 47.4 M
Market Cap
-1.54
P/E
1. INTRINSIC VALUE

Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and J-Plasma branded products for the hospital surgical market. It also develops, manufactures, and sells disposable hand pieces, and OEM generators and accessories.[ Read More ]

The intrinsic value of one APYX stock under the base case scenario is HIDDEN Compared to the current market price of 1.26 USD, Apyx Medical Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart APYX

image
FINANCIALS
52.3 M REVENUE
17.61%
-17.3 M OPERATING INCOME
26.75%
-18.8 M NET INCOME
19.02%
-5.25 M OPERATING CASH FLOW
74.12%
6.88 M INVESTING CASH FLOW
781.29%
32 M FINANCING CASH FLOW
14655.30%
16 M REVENUE
31.86%
-3.64 M OPERATING INCOME
34.47%
-4.77 M NET INCOME
27.27%
-4.44 M OPERATING CASH FLOW
-2.56%
-153 K INVESTING CASH FLOW
47.06%
-5 K FINANCING CASH FLOW
-0.00%
Balance Sheet Decomposition Apyx Medical Corporation
image
Current Assets 70.4 M
Cash & Short-Term Investments 43.7 M
Receivables 14.1 M
Other Current Assets 12.7 M
Non-Current Assets 8.88 M
Long-Term Investments 0
PP&E 7.15 M
Other Non-Current Assets 1.73 M
Current Liabilities 12.7 M
Accounts Payable 2.71 M
Short-Term Debt 734 K
Other Current Liabilities 9.29 M
Non-Current Liabilities 39.6 M
Long-Term Debt 38.1 M
Other Non-Current Liabilities 1.44 M
EFFICIENCY
Earnings Waterfall Apyx Medical Corporation
image
Revenue 52.3 M
Cost Of Revenue 38.2 M
Gross Profit 14.1 M
Operating Expenses 51 M
Operating Income -17.3 M
Other Expenses 1.59 M
Net Income -18.8 M
RATIOS
26.98% GROSS MARGIN
26.98%
-32.97% OPERATING MARGIN
-32.97%
-35.75% NET MARGIN
-35.75%
-70.08% ROE
-70.08%
-23.62% ROA
-23.62%
-25.37% ROIC
-25.37%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Apyx Medical Corporation
image
Net Income -18.8 M
Depreciation & Amortization 692 K
Capital Expenditures -533 K
Stock-Based Compensation 5.11 M
Change in Working Capital 5.54 M
Others 2.34 M
Free Cash Flow -5.78 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Apyx Medical Corporation
image
Wall Street analysts predict an average 1-year price target for APYX of $11.3 , with forecasts ranging from a low of $5 to a high of $17 .
APYX Lowest Price Target Wall Street Target
5 USD 296.83%
APYX Average Price Target Wall Street Target
11.3 USD 799.47%
APYX Highest Price Target Wall Street Target
17 USD 1249.21%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Apyx Medical Corporation
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
6.03 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
84 K USD 2
9-12 MONTHS
Date Value Insider Amount Avg Price
3 months ago
Aug 13, 2024
Bought 6.03 K USD
HILL MATTHEW C
Chief Financial Officer
+ 5336
1.13 USD
11 months ago
Dec 12, 2023
Bought 5.48 K USD
HILL MATTHEW C
Chief Financial Officer
+ 2500
2.19 USD
1 year ago
Nov 14, 2023
Bought 78.5 K USD
Goodwin Charles D. II
Chief Executive Officer
+ 50000
1.57 USD
1 year ago
Jun 26, 2023
Sell 113 K USD
Hornsby Todd
Executive Vice President
- 15000
7.56 USD
1 year ago
Jun 26, 2023
Sell 113 K USD
Hornsby Todd
Executive Vice President
- 15000
7.56 USD
2 years ago
Aug 29, 2022
Bought 58.2 K USD
Goodwin Charles D. II
Chief Executive Officer
+ 9750
5.97 USD
4 years ago
May 13, 2020
Bought 93.2 K USD
Goodwin Charles D. II
Chief Executive Officer
+ 28250
3.299 USD
8 years ago
Aug 17, 2016
Bought 299 K USD
McCarthy John J. III
Chief CommercializationOfficer
+ 90750
3.3 USD
8 years ago
Dec 21, 2015
Bought 36.8 K USD
CITRONOWICZ MOSHE
Sr. V.P. of Operations
+ 20000
1.8387 USD
8 years ago
Dec 22, 2015
Bought 49.4 K USD
McCarthy John J. III
Chief Commercialization Office
+ 25000
1.9771 USD
8 years ago
Dec 21, 2015
Bought 18.2 K USD
Gershon Robert
Chief Executive Officer
+ 10000
1.8168 USD
9 years ago
Aug 14, 2015
Bought 47.8 K USD
Gershon Robert
Chief Executive Officer
+ 20000
2.39 USD
12 years ago
Dec 23, 2011
Sell 1.8 K USD
Konesky Gregory Alan
Director
- 750
2.4 USD
13 years ago
Aug 25, 2011
Bought 19.2 K USD
RENN Universal Growth Investment Trust
Director
+ 7100
2.7 USD
13 years ago
Aug 24, 2011
Bought 37.5 K USD
RENN Universal Growth Investment Trust
Director
+ 14100
2.6618 USD
13 years ago
Aug 23, 2011
Bought 29.6 K USD
RENN Universal Growth Investment Trust
Director
+ 11600
2.55 USD
13 years ago
Aug 09, 2011
Bought 245 K USD
RENN Universal Growth Investment Trust
10 percent owner
+ 100000
2.45 USD
13 years ago
Aug 09, 2011
Bought 31.3 K USD
RENN Universal Growth Investment Trust
10 percent owner
+ 15000
2.09 USD
13 years ago
Jun 08, 2011
Sell 14.4 K USD
KROMER GEORGE W
Director
- 5000
2.87 USD
13 years ago
May 20, 2011
Sell 2.39 K USD
Konesky Gregory Alan
Director
- 800
2.99 USD
13 years ago
Mar 07, 2011
Bought 386 K USD
RENN Universal Growth Investment Trust
10 percent owner
+ 150000
2.57 USD
13 years ago
Dec 01, 2010
Sell 12.1 K USD
Pardoll Peter
Director
- 3700
3.26 USD
13 years ago
Dec 02, 2010
Sell 8.34 K USD
Pardoll Peter
Director
- 2700
3.09 USD
13 years ago
Dec 03, 2010
Sell 18.7 K USD
Pardoll Peter
Director
- 6078
3.08 USD
13 years ago
Dec 01, 2010
Sell 3.26 K USD
Pardoll Peter
Director
- 1000
3.26 USD
13 years ago
Dec 02, 2010
Sell 45.8 K USD
Pardoll Peter
Director
- 14778
3.1 USD
14 years ago
Sep 17, 2010
Sell 1.8 K USD
Konesky Gregory Alan
Director
- 750
2.4 USD
14 years ago
Mar 29, 2010
Sell 6.45 K USD
Konesky Gregory Alan
Director
- 1000
6.45 USD
15 years ago
May 26, 2009
Sell 231 K USD
MAKRIDES ANDREW
CEO
- 32500
7.1 USD
15 years ago
May 27, 2009
Sell 176 K USD
MAKRIDES ANDREW
CEO
- 25000
7.02 USD
15 years ago
May 21, 2009
Sell 281 K USD
MAKRIDES ANDREW
CEO
- 39000
7.2 USD
15 years ago
May 22, 2009
Sell 60.3 K USD
MAKRIDES ANDREW
CEO
- 8500
7.09 USD
15 years ago
May 13, 2009
Sell 64.3 K USD
KROMER GEORGE W
Director
- 9000
7.14 USD
15 years ago
May 12, 2009
Sell 110 K USD
SARON J ROBERT
Chief Sales & Mkt Officer
- 15000
7.33 USD
15 years ago
May 12, 2009
Sell 101 K USD
CITRONOWICZ MOSHE
Chief Operating Officer
- 13500
7.45 USD
15 years ago
Apr 15, 2009
Sell 45.9 K USD
CITRONOWICZ MOSHE
Chief Operating Officer
- 6500
7.06 USD
15 years ago
Apr 08, 2009
Sell 120 K USD
CITRONOWICZ MOSHE
Chief Operating Officer
- 19000
6.31 USD
15 years ago
Apr 09, 2009
Sell 133 K USD
CITRONOWICZ MOSHE
Chief Operating Officer
- 21000
6.34 USD
15 years ago
Apr 06, 2009
Sell 14 K USD
SARON J ROBERT
Chief Sales & Mkt Officer
- 2200
6.35 USD
15 years ago
Apr 07, 2009
Sell 85.6 K USD
SARON J ROBERT
Chief Sales & Mkt Officer
- 13500
6.34 USD
15 years ago
Apr 02, 2009
Sell 82.7 K USD
SARON J ROBERT
Chief Sales & Mkt Officer
- 12700
6.51 USD
15 years ago
Apr 03, 2009
Sell 25.9 K USD
SARON J ROBERT
Chief Sales & Mkt Officer
- 4100
6.31 USD
15 years ago
Mar 31, 2009
Sell 58.4 K USD
SARON J ROBERT
Chief Sales & Mkt Officer
- 8800
6.64 USD
15 years ago
Apr 01, 2009
Sell 23.9 K USD
SARON J ROBERT
Chief Sales & Mkt Officer
- 3700
6.46 USD
16 years ago
Sep 19, 2008
Sell 157 K USD
CITRONOWICZ MOSHE
Chief Operating Officer
- 21700
7.23 USD
16 years ago
Sep 17, 2008
Sell 132 K USD
CITRONOWICZ MOSHE
Chief Operating Officer
- 18300
7.19 USD
16 years ago
Feb 15, 2008
Bought 12 K USD
MADDEN BRIAN
Director
+ 2000
6.01 USD
17 years ago
Aug 23, 2007
Sell 15.7 K USD
Rossi Randy D
Director
- 2200
7.13 USD
17 years ago
May 23, 2007
Sell 63.7 K USD
Rossi Randy D
Director
- 9000
7.08 USD
17 years ago
May 21, 2007
Bought 21.2 K USD
MADDEN BRIAN
Director
+ 3000
7.07 USD
17 years ago
May 08, 2007
Sell 45.1 K USD
Rossi Randy D
Director
- 6000
7.52 USD
17 years ago
Mar 06, 2007
Bought 19.6 K USD
MADDEN BRIAN
Director
+ 2500
7.85 USD
17 years ago
Feb 13, 2007
Sell 95.7 K USD
CITRONOWICZ MOSHE
Vice President of Operations
- 10491
9.125 USD
17 years ago
Feb 08, 2007
Sell 56.5 K USD
CITRONOWICZ MOSHE
Vice President of Operations
- 6200
9.116 USD
17 years ago
Feb 09, 2007
Sell 30.1 K USD
CITRONOWICZ MOSHE
Vice President of Operations
- 3309
9.101 USD
17 years ago
Jan 24, 2007
Sell 58.6 K USD
SARON J ROBERT
Vice President
- 6700
8.7476 USD
17 years ago
Jan 25, 2007
Sell 98.5 K USD
SARON J ROBERT
Vice President
- 11300
8.7198 USD
17 years ago
Jan 19, 2007
Sell 172 K USD
KROMER GEORGE W
Director
- 20000
8.6089 USD
17 years ago
Jan 11, 2007
Sell 128 K USD
MAKRIDES ANDREW
President
- 14400
8.9217 USD
17 years ago
Jan 12, 2007
Sell 92.3 K USD
MAKRIDES ANDREW
President
- 10600
8.7074 USD
18 years ago
Feb 24, 2006
Sell 9.15 K USD
SARON J ROBERT
VP of Marketing
- 3000
3.05 USD
18 years ago
Feb 27, 2006
Sell 9.15 K USD
SARON J ROBERT
VP of Marketing
- 3000
3.051 USD
18 years ago
Feb 21, 2006
Sell 9.15 K USD
SARON J ROBERT
VP of Marketing
- 3000
3.05 USD
18 years ago
Feb 22, 2006
Sell 9.15 K USD
SARON J ROBERT
VP of Marketing
- 3000
3.05 USD
18 years ago
Feb 23, 2006
Sell 9.15 K USD
SARON J ROBERT
VP of Marketing
- 3000
3.05 USD
19 years ago
May 10, 2005
Bought 4.48 K USD
GRECO ALFRED V
Director
+ 2000
2.24 USD
19 years ago
May 12, 2005
Sell 6.78 K USD
GRECO ALFRED V
Director
- 3000
2.26 USD
18 years ago
Jan 06, 2006
Sell 29.6 K USD
CITRONOWICZ MOSHE
VP of Operations
- 10000
2.96 USD
19 years ago
Jan 06, 2005
Sell 29.6 K USD
CITRONOWICZ MOSHE
VP of Operations
- 10000
2.96 USD
18 years ago
Dec 21, 2005
Sell 42.9 K USD
CITRONOWICZ MOSHE
Vice President of Operations
- 15000
2.86 USD
18 years ago
Dec 01, 2005
Sell 28.8 K USD
PEABODY CHARLES
- 10000
2.88 USD
18 years ago
Dec 02, 2005
Sell 57 K USD
PEABODY CHARLES
- 20000
2.85 USD
19 years ago
May 12, 2005
Sell 6.78 K USD
GRECO ALFRED V
Director
- 3000
2.26 USD
19 years ago
May 10, 2005
Bought 4.48 K USD
GRECO ALFRED V
Director
+ 2000
2.24 USD
20 years ago
Sep 24, 2004
Bought 5.25 M USD
ACMI CORP
10 percent owner
+ 3000000
1.75 USD
20 years ago
Jul 12, 2004
Sell 28.2 K USD
GRECO ALFRED V
Director
- 10000
2.82 USD
7. News
Apyx Medical Corporation to Attend 15th Annual Craig-Hallum Alpha Select Conference CLEARWATER, Fla., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced that Charles Goodwin, President and CEO and Matt Hill, CFO will be attending the following upcoming conference: globenewswire.com - 4 days ago
Apyx Medical Corporation (APYX) Q3 2024 Earnings Call Transcript Apyx Medical Corporation (NASDAQ:APYX ) Q3 2024 Earnings Call Transcript November 8, 2024 8:00 AM ET Company Participants Jeremy Feffer - MD, LifeSci Advisors Stavros Vizirgianakis - Executive Chairman Charlie Goodwin - CEO Matt Hill - CFO Conference Call Participants Matthew O'Brien - Piper Sandler Matt Hewitt - Craig-Hallum Capital Group Sam Eiber - BTIG Ben Haynor - Lake Street Capital Markets Operator Ladies and gentlemen, good morning, and welcome to the Apyx Medical Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com - 1 week ago
Apyx Medical (APYX) Reports Q3 Loss, Lags Revenue Estimates Apyx Medical (APYX) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.13 per share a year ago. zacks.com - 1 week ago
Apyx Medical Corporation Announces $7,000,000 Million Registered Direct Offering CLEARWATER, Fla., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical” or the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced it has entered into a definitive purchase agreement with Nantahala Capital for the purchase and sale in a registered direct offering of 3,000,000 shares of the Company's common stock at a purchase price of $1.18 per share and pre-funded warrants to purchase up to 2,934,690 shares of the Company's common stock at a purchase price of $1.179 per pre-funded warrant (which represents the per share offering price for common stock less the exercise price per share for each pre-funded warrant of $0.001). The gross proceeds to Apyx Medical from the offering were approximately $7,000,000, before deducting offering expenses payable by the Company. The offering closed on November 8, 2024. globenewswire.com - 1 week ago
Apyx Medical Corporation Reports Third Quarter 2024 Financial Results; Updates Full Year 2024 Financial Outlook and Introduces Full Year 2025 Financial Outlook CLEARWATER, Fla., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today reported the financial results for its third quarter ended September 30, 2024, updated its financial expectations for the full year ending December 31, 2024, and introduced its financial expectations for the full year ending December 31, 2025. globenewswire.com - 1 week ago
Apyx Medical Corporation to Release Third Quarter Of Fiscal Year 2024 Financial Results on November 8, 2024 CLEARWATER, Fla., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Apyx® Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced that financial results for the third quarter of fiscal year 2024 will be released before the market opens on Friday, November 8th. globenewswire.com - 3 weeks ago
Apyx (APYX) Upgraded to Buy: Here's What You Should Know Apyx (APYX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com - 1 month ago
Renuvion Named #1 Trusted Body Contouring Technology by Doctors* Independent survey reveals Renuvion is #1 trusted body contouring technology* with plastic and cosmetic surgeons. CLEARWATER, Fla. prnewswire.com - 3 months ago
Apyx Medical Corporation (APYX) Q2 2024 Earnings Call Transcript Apyx Medical Corporation (NASDAQ:APYX ) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Charles Goodwin - President, Chief Executive Officer & Director Matthew Hill - Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Capital Frank Takkinen - Lake Street Capitals George Sellers - Stephens Inc Operator Hello, and welcome, ladies and gentlemen, to the Second Quarter of Fiscal Year 2024 Earnings Conference Call for Apyx Medical Corporation. At this time all participants have been placed in a listen-only more. seekingalpha.com - 3 months ago
Apyx Medical (APYX) Reports Q2 Loss, Lags Revenue Estimates Apyx Medical (APYX) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.11 per share a year ago. zacks.com - 3 months ago
Apyx Medical Corporation Launches the "Renewing Lives" Give-Back Campaign Providing Treatments with Renuvion to Benefit Physical Appearance and Mental Health Renuvion is the only device FDA-cleared for contracting subcutaneous tissue  CLEARWATER, Fla. , June 26, 2024 /PRNewswire/ -- Apyx® Medical Corporation (NASDAQ: APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the launch of the "Renewing Lives" campaign, a nationwide, life-changing give-back program that will provide Renuvion treatments to people who can most benefit from this advanced medical technology. prnewswire.com - 4 months ago
Apyx Medical Corporation (APYX) Q1 2024 Earnings Call Transcript Apyx Medical Corporation (NASDAQ:APYX ) Q1 2024 Results Conference Call May 9, 2024 8:00 AM ET Company Participants Charles Goodwin - President, Chief Executive Officer & Director Matt Hill - Chief Financial Officer Conference Call Participants Phillip Paul Dantoin - Piper Sandler Frank Takkinen - Lake Street Capitals Matt Hewitt - Craig-Hallum Capital George Sellers - Stephens Inc Operator Hello, and welcome, ladies and gentlemen, to the First Quarter of Fiscal Year 2024 Earnings Conference Call for Apyx Medical Corporation. [Operator Instructions]. seekingalpha.com - 6 months ago
8. Profile Summary

Apyx Medical Corporation APYX

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 47.4 M
Dividend Yield 0.00%
Description Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and J-Plasma branded products for the hospital surgical market. It also develops, manufactures, and sells disposable hand pieces, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
Contact 5115 Ulmerton Road, Clearwater, FL, 33760 https://www.apyxmedical.com
IPO Date Jan. 2, 2019
Employees 252
Officers Mr. Charles D. Goodwin II President, Chief Executive Officer & Director Mr. Matthew C. Hill CPA Chief Financial Officer, Treasurer & Secretary Mr. Stavros George Vizirgianakis B.Com. Executive Chairman Mr. Moshe Citronowicz Senior Vice President Mr. Todd Hornsby Executive Vice President